GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Pramipexole extended-release (MIRAPEX ER)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

Mirapex ER

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
URL name does not establish immediate-release formulation

The /mirapex-drug/ page body reviewed for this import describes MIRAPEX ER.

Before applying: Use this entry only for the extended-release product; do not transfer its renal schedule to immediate-release pramipexole.

MIRAPEX URL: retrieved body identifies extended release

The generic-looking mirapex URL displays MIRAPEX ER instructions. Its URL title is not sufficient evidence for immediate-release dosing.

Before applying: Use this source only within its explicitly identified ER scope. Keep the separate official IR record and RLS instructions distinct.

Also check: URL name does not establish immediate-release formulation; MIRAPEX URL: retrieved body identifies extended release

Rxlist source

GlobalRPh RX List - MIRAPEX ER

Product / population
Pramipexole - MIRAPEX ER source-identity warning; selected renal passages, not a complete prescribing monograph.
Renal measure
Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Not an IR source. URL wording is insufficient to establish product identity.

Renal dosing, restrictions and evidence limits

SOURCE-IDENTITY WARNING: although the URL is mirapex, the retrieved prescribing body is MIRAPEX ER. Its CrCl 30-50 mL/min instructions start with every-other-day dosing, assess tolerance before daily dosing after 1 week, and permit further 0.375 mg increments no more often than weekly up to 2.25 mg/day. ER is not recommended below CrCl 30 or with hemodialysis because it was not studied. Do not use this page as an immediate-release or restless-legs dosing source. The separate official immediate-release record supplies its own renal table.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/mirapex-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - Mirapex ER

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

The RX List URL says mirapex, but its prescribing body is explicitly MIRAPEX ER. This record is ER only, not immediate-release.

Renal method: CrCl, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - MIRAPEX ER

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Pramipexole - MIRAPEX ER source-identity warning; selected renal passages, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

MIRAPEX URL: retrieved body identifies extended release

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

formulation

URL name does not establish immediate-release formulation

The /mirapex-drug/ page body reviewed for this import describes MIRAPEX ER.

How to use this: Use this entry only for the extended-release product; do not transfer its renal schedule to immediate-release pramipexole.

GlobalRPh RX List - Mirapex ER

Source difference identified; final patient-specific adjudication required.

formulation scope

MIRAPEX URL: retrieved body identifies extended release

The generic-looking mirapex URL displays MIRAPEX ER instructions. Its URL title is not sufficient evidence for immediate-release dosing.

How to use this: Use this source only within its explicitly identified ER scope. Keep the separate official IR record and RLS instructions distinct.

GlobalRPh RX List - MIRAPEX ERPramipexole - immediate-release tablets

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - Mirapex ERGlobalRPh RX List - MIRAPEX ER
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/mirapex-drug/

Product and population scope

The RX List URL says mirapex, but its prescribing body is explicitly MIRAPEX ER. This record is ER only, not immediate-release.

RDM33-SCOPE-pramipexole-mirapex-er-C1 · Source section: Exact product identity and selected populationRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Mirapex ER

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · The RX List URL says mirapex, but its prescribing body is explicitly MIRAPEX ER. This record is ER only, not immediate-release.

Renal method: CrCl, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For CrCl 30 to 50 mL/min, initiate the extended-release product every other day. After one week, careful assessment of tolerability and response may allow daily administration. Subsequent increments are 0.375 mg, no more often than weekly, up to 2.25 mg once daily. No reduction is recommended above 50 mL/min. This ER product is not recommended below 30 mL/min or in hemodialysis. Use the full ER label to select the starting strength; do not substitute an immediate-release renal table.

RDM33-rxlist-pramipexole-mirapex-er-C1 · Source locator: Dosage and administration: renal impairment; use in specific populations: renal impairment.

Source-specific limits

Product-identity warning: URL/heading is not sufficient to identify formulation.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/mirapex-drug/
Retrieved
2026-09-07
Renal-function method
CrCl, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
09d2de906b31620a281dce9b1e37c31929203b0411f8135e749a4ce40bae6518
Rxlist

GlobalRPh RX List - MIRAPEX ER

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Pramipexole - MIRAPEX ER source-identity warning; selected renal passages, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

SOURCE-IDENTITY WARNING: although the URL is mirapex, the retrieved prescribing body is MIRAPEX ER. Its CrCl 30-50 mL/min instructions start with every-other-day dosing, assess tolerance before daily dosing after 1 week, and permit further 0.375 mg increments no more often than weekly up to 2.25 mg/day. ER is not recommended below CrCl 30 or with hemodialysis because it was not studied. Do not use this page as an immediate-release or restless-legs dosing source. The separate official immediate-release record supplies its own renal table.

RDM50-rxlist-pramipexole-mirapex-er-d706416bd0-C1 · Source locator: ER formulation and renal dosage, lines 32-49 and 54-73; URL/title identity checked.

Source-specific limits

Not an IR source. URL wording is insufficient to establish product identity.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/mirapex-drug/
Retrieved
2026-09-09
Renal-function method
Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
2023c7cf11220ad2bec52a12b1d7f4a538f6c80234b512440acbad8edfa75b7e

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/mirapex-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
346e3d66d64d2203bd042a349696ad49195849b114fce3c511642e0e1bf2d562
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report